News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,130 Results
Type
Article (2565)
Company Profile (45)
Press Release (37519)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14232)
Career Advice (78)
Deals (2114)
Drug Delivery (9)
Drug Development (4143)
Employer Resources (10)
FDA (444)
Job Trends (781)
News (20317)
Policy (1055)
Tag
Academia (144)
Allergies (7)
Alliances (3493)
ALS (6)
Alzheimer's disease (57)
Antibody-drug conjugate (ADC) (26)
Approvals (449)
Artificial intelligence (30)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (43)
Cancer (321)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (29)
CDC (1)
Cell therapy (79)
Cervical cancer (2)
Clinical research (3431)
Collaboration (196)
Company closure (2)
Compensation (102)
COVID-19 (183)
CRISPR (11)
C-suite (105)
Cystic fibrosis (7)
Data (408)
Denatured (6)
Depression (13)
Diabetes (17)
Diagnostics (484)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (33)
Drug pricing (10)
Duchenne muscular dystrophy (39)
Earnings (4536)
Editorial (4)
Employer branding (1)
Employer resources (8)
Events (6422)
Executive appointments (135)
FDA (582)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (164)
Gene editing (31)
Generative AI (1)
Gene therapy (52)
GLP-1 (63)
Government (157)
Guidances (23)
Healthcare (710)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (33)
Immuno-oncology (12)
Indications (4)
Infectious disease (194)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1008)
IRA (7)
Job creations (293)
Job search strategy (62)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (49)
MASH (13)
Medical device (313)
Medtech (313)
Mergers & acquisitions (1215)
Metabolic disorders (69)
Multiple sclerosis (21)
Neurodegenerative disease (25)
Neuropsychiatric disorders (9)
Neuroscience (160)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (10)
Obesity (30)
Opinion (17)
Ovarian cancer (17)
Pain (23)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (52)
Patient recruitment (25)
Peanut (1)
People (5865)
Pharmaceutical (5)
Phase I (1473)
Phase II (1699)
Phase III (913)
Pipeline (368)
Policy (15)
Postmarket research (30)
Preclinical (641)
Press Release (2)
Prostate cancer (7)
Psychedelics (2)
Radiopharmaceuticals (14)
Rare diseases (56)
Real estate (426)
Recruiting (5)
Regulatory (908)
Reports (7)
Research institute (147)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
Schizophrenia (16)
Series A (44)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (497)
Stomach cancer (2)
Supply chain (4)
Tariffs (1)
The Weekly (3)
Vaccines (49)
Venture capital (14)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Today (7)
Last 7 days (26)
Last 30 days (149)
Last 365 days (2456)
2026 (120)
2025 (2460)
2024 (2627)
2023 (2886)
2022 (3783)
2021 (4076)
2020 (3473)
2019 (2061)
2018 (1554)
2017 (1796)
2016 (1625)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (44)
Alabama (3)
Arizona (17)
Asia (1942)
Australia (306)
California (1566)
Canada (238)
China (79)
Colorado (81)
Connecticut (16)
Delaware (5)
Europe (4007)
Florida (63)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (20)
India (2)
Indiana (56)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (47)
Massachusetts (553)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (129)
New York (80)
North Carolina (131)
Northern California (759)
Ohio (42)
Oklahoma (2)
Oregon (5)
Pennsylvania (107)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (640)
Tennessee (4)
Texas (151)
United States (3162)
Utah (4)
Virginia (11)
Washington D.C. (2)
Washington State (93)
West Virginia (1)
Wisconsin (12)
40,130 Results for "aytu bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
January 14, 2026
·
1 min read
Press Releases
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
January 12, 2026
·
9 min read
Press Releases
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
December 19, 2025
·
4 min read
Press Releases
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
October 29, 2025
·
6 min read
Press Releases
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 13, 2025
·
1 min read
Press Releases
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
November 14, 2025
·
16 min read
Press Releases
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 25, 2025
·
1 min read
Press Releases
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 25, 2025
·
1 min read
Press Releases
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
November 5, 2025
·
1 min read
Press Releases
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
December 16, 2025
·
5 min read
1 of 4,013
Next
